84. Sarcoidosis
143 clinical trials,   221 drugs   (DrugBank: 79 drugs),   82 drug target genes,   165 drug target pathways

Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-004887-74-DE
(EUCTR)
20/05/202017/06/2019A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension.A Multicenter, Randomized, Double-blind, Placebo-controlled study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. sarcoidosis-associated pulmonary hypertension (SAPH)
MedDRA version: 21.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Uptravi
Product Name: Selexipag
Product Code: ACT-293987 / JNJ-67896049
INN or Proposed INN: SELEXIPAG
Other descriptive name: SELEXIPAG
Actelion Pharmaceuticals LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
74Phase 2United States;Spain;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Belgium;Brazil;Poland;Germany;Netherlands
2EUCTR2018-004887-74-GB
(EUCTR)
14/08/201903/06/2019A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension.A Multicenter, Randomized, Double-blind, Placebo-controlled Study inParticipants with Sarcoidosis-associated Pulmonary Hypertension (SAPH)to Assess the Efficacy and Safety of Oral Selexipag. sarcoidosis-associated pulmonary hypertension (SAPH)
MedDRA version: 21.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Uptravi
Product Name: Selexipag
Product Code: ACT-293987 / JNJ-67896049
INN or Proposed INN: SELEXIPAG
Other descriptive name: SELEXIPAG
Actelion Pharmaceuticals LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
74Phase 2United States;Czechia;Spain;United Kingdom;Italy;France;Hungary;Canada;Belgium;Brazil;Poland;Germany;Netherlands
3EUCTR2018-004887-74-NL
(EUCTR)
29/07/201905/06/2019A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension.A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. sarcoidosis-associated pulmonary hypertension (SAPH)
MedDRA version: 21.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Uptravi
Product Name: Selexipag
Product Code: ACT-293987 / JNJ-67896049
INN or Proposed INN: SELEXIPAG
Other descriptive name: SELEXIPAG
Actelion Pharmaceuticals LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
74Phase 2United States;France;Hungary;Canada;Poland;Spain;Brazil;Belgium;Germany;Netherlands;United Kingdom;Italy